Want to see TGTX full AI Analyst Report?
TGTX Stock Chart & Stats
$56.04
$0.54(0.97%)
At close: 4:00 PM EDT
$56.04
$0.54(0.97%)
Day’s Range― - ―
52-Week Range$25.28 - $59.30
Previous CloseN/A
Volume1.44M
Average Volume (3M)2.53M
Market Cap
$8.53B
Enterprise Value$5.56K
Total Cash (Recent Filing)$514.43M
Total Debt (Recent Filing)$753.56M
Price to Earnings (P/E)17.3
Beta0.62
Next Earnings
Aug 03, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.18
Shares Outstanding153,083,570
10 Day Avg. Volume1,944,033
30 Day Avg. Volume2,529,227
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$63.86Price Target Upside13.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.32
Revenue Forecast (FY)$942.33M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And GuidanceSustained patient uptake and consecutive quarterly growth underpin a durable revenue base. Management's raised guidance and an expected near‑$1B annualized run‑rate signal stronger channel adoption, broader physician acceptance, and scalable commercial execution that can support multi‑period revenue visibility and reinvestment.
High Gross And Net MarginsExceptional gross and net margins indicate powerful unit economics and pricing power in the BRIUMVI franchise. Margin sustainability supports cash generation potential (if converted) and allows reinvestment into lifecycle programs, R&D, and commercial expansion even as revenue growth normalizes.
Stronger Balance Sheet And Cash BufferA large cash balance and very low debt materially reduce refinancing and liquidity risk while enabling aggressive share repurchases and funding of subcutaneous scale‑up. This balance sheet strength supports near‑term R&D and manufacturing investments without forcing dilutive financing.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow despite strong reported net income weakens earnings quality and implies working‑capital or noncash drivers. Until cash conversion improves, the company faces execution risk funding operations and may need to rely on cash reserves for growth investments.
Material Gross-to-net/rebate PressureA sustained ~65% gross‑to‑net burden materially reduces realized revenue and limits margin expansion even if list sales grow. This structural payer and rebate dynamic can compress long‑term cash flows and necessitates continued payer strategy, potentially slowing net revenue per patient.
Shareholder Governance ConcernA failed say‑on‑pay vote signals investor dissatisfaction with compensation alignment and can trigger board scrutiny, potential management turnover, or policy changes. Governance tension may distract management, complicate incentive structures, and affect retention during a critical commercial and clinical expansion phase.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $59.30 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $8.53B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 03, 2026 which is in 4 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on May 06, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.275 by -$0.155.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.31.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,083,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.12 in its last earnings report, missing expectations of $0.275. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$63.86 (13.95% Upside)
$63.86 (13.95% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 536.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc. (TGTX) is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell–mediated diseases, particularly within neurology and immunology. The company’s core commercial product is BRIUMVI (ublituximab-xiiy), a monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS).
TGTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum: record Q1 revenue, 63% YoY U.S. growth, rising patient counts (25,000+), improved profitability, a robust cash position and aggressive share buybacks. Management also highlighted multiple near‑term clinical catalysts (ENHANCE, subcutaneous readouts) and longer‑term expansion opportunities (subcutaneous formulation, additional indications). Offsetting this optimism are near‑term expense increases (including ~$100M subcutaneous spend), a one‑time refinancing charge, notable gross‑to‑net/rebate pressure (~65% guidance), and clinical/regulatory timing and outcome risks for key lifecycle programs and the azer‑cel program. Overall, the positives (strong revenue beats, guidance raises, cash and buybacks, lifecycle catalysts, and supportive long‑term data) materially outweigh the listed challenges, though execution and trial outcomes remain critical to sustaining the trajectory.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$63.86
▲(13.95% Upside)
Technical Analysis
Protagonist Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Legend Biotech
―
Kymera Therapeutics
―
Ownership Overview
7.54% Insiders
18.43% Mutual Funds
1.96% Other Institutional Investors
47.22% Public Companies and
Individual Investors